脑再生科技（RGC）在周一夜盘交易中再度大涨26.95%，延续了其令人瞩目的上涨势头。据悉，该公司股价年内已累计上涨超过51,000%，成为市场焦点。
此轮涨势与多个因素相关。首先，脑再生科技近期宣布进行38比1的股票拆分，新股已于6月16日开始交易。这一举措旨在提高公司普通股的市场流动性，使投资者更容易获得股票。其次，作为脑机接口概念股，脑再生科技受益于行业热度。今年3月，中国国家医保局为脑机接口技术单独立项，设立了相关价格项目，推动其商业化。
然而，投资者需要谨慎看待脑再生科技的股价表现。作为一家专注于研发治疗神经认知障碍中药的早期生物科技公司，脑再生科技目前尚未实现盈利。公司2021至2024财年的营收均为0，且在2024财年财报中明确表示"可能永远无法盈利"。此外，公司股票流通性较低，截至2024年6月底，仅有11.2%的股份在市场流通，这种低流通性可能加剧了股价的波动。投资者在关注该股票时应当充分评估相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.